Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04941521 · ClinicalTrials.gov registry record · Phase 1
Exenatide for Treating Cocaine Use Disorder
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04941521 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 3 participants.
The verdict
NCT04941521, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information about whether exenatide (Bydureon) may be safe and helpful as a medication treatment for individuals who want to stop using cocaine. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by the FDA to treat cocaine use; therefore, it is called an investigational drug.
Interventions
- DRUG Exenatide 2 mg [Bydureon]
- BEHAVIORAL Drug Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2021-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04941521
The ClinicalTrials.gov registry entry for NCT04941521 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exenatide 2 mg [Bydureon] is the first listed.
NCT04941521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04941521 about?
NCT04941521 is a clinical study titled "Exenatide for Treating Cocaine Use Disorder". The purpose of this study is to collect information about whether exenatide (Bydureon) may be safe and helpful as a medication treatment for individuals who want to stop using cocaine. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 di...
What is the current status of trial NCT04941521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-06-24. Estimated completion is 2021-11-17.
What interventions are being tested in trial NCT04941521?
The interventions under investigation include: Exenatide 2 mg [Bydureon] (DRUG), Drug Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04941521?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.